• Patient-Derived 3D Spheroids in Prostate Cancer

  2026-08-16

  Linxweiler and colleagues established viable three-dimensional spheroids from radical prostatectomy specimens, creating a clinically relevant model for organ-confined prostate cancer. The cultures retained key epithelial and prostate cancer markers, supported cryopreservation and long-term maintenance, and revealed stronger responses to bicalutamide and enzalutamide than to docetaxel or abiraterone under the tested conditions.

• Phage-Layer Interferometry for Phage Therapy

  2026-08-15

  The reference study introduces phage-layer interferometry (PLI), a time-resolved, label-free platform for screening therapeutic bacteriophages and detecting bacteria in complex media. By distinguishing phage binding from subsequent lysis and operating in opaque samples such as baby formula, PLI addresses limitations of plaque-based and bulk optical assays.

• Digoxin Assay Reliability: 5 Lab Scenarios

  2026-08-14

  This scenario-driven guide shows how Digoxin, SKU B7684, can support better-controlled cell viability, cytotoxicity, cardiac, and chikungunya virus experiments. It connects mechanism, DMSO stock preparation, cell-type limitations, data interpretation, and supplier documentation to practical laboratory decisions.

• Tin Mesoporphyrin IX (chloride) in HO Assays

  2026-08-14

  Learn how Tin Mesoporphyrin IX (chloride), SKU C5606, can help researchers distinguish heme oxygenase pathway effects from nonspecific changes in cell viability, proliferation, and cytotoxicity assays. This scenario-based guide covers mechanism, solvent compatibility, protocol design, interpretation, and practical supplier-selection criteria.

• Coumestrol-Driven Ferroptosis in RA Synoviocytes

  2026-08-13

  The reference study identifies a TRIM3–PMAIP1 regulatory axis through which Coumestrol promotes ferroptosis in rheumatoid arthritis fibroblast-like synoviocytes. Its findings connect mitochondrial protein stability with reduced synoviocyte proliferation and inflammatory cytokine production, while also defining important limits for translating this in vitro mechanism to therapeutic research.

• Mycobacterium tuberculosis WecA: Expression and Kinetics

  2026-08-13

  Zhao and colleagues establish a practical route to obtain active Mycobacterium tuberculosis WecA, an otherwise difficult 11-transmembrane-domain enzyme and potential anti-tuberculosis target. Their combination of tunable expression, affinity purification, mass-spectrometric identification, UMP-based activity detection, and competitive inhibition analysis creates a foundation for mechanistic studies and WecA inhibitor discovery.

• GSH-Responsive MOF Nanoparticles for Melanoma Therapy

  2026-08-12

  Hao et al. developed a glutathione-responsive metal–organic framework nanoparticle that combines indocyanine green photothermal therapy with AUNP12-mediated PD-1/PD-L1 checkpoint blockade. The study shows how stimulus-responsive release and near-infrared irradiation can be integrated to promote tumor-cell killing, dendritic-cell maturation, and immune activation, while also highlighting the translational questions that remain.

• Digoxin Workflows for Cardiac and Antiviral Research

  2026-08-12

  Build mechanism-centered assays around Digoxin, from Na+/K+ ATPase perturbation and calcium signaling to cell-type-specific chikungunya studies. This workflow pairs formulation guidance with disease-state pharmacokinetic thinking, helping researchers distinguish true biology from vehicle, exposure, and matrix effects.

• From Nicotine Biosynthesis to Translational Tool Design

  2026-08-11

  Chang et al.’s complete reconstruction of nicotine biosynthesis reframes nicotine as the endpoint of a coordinated, compartmentalized pathway rather than a simple small-molecule product. This thought-leadership analysis shows how 3-(1-methylpyrrolidin-2-yl)pyridine (N2703) can support mechanism-first assay design while keeping pathway evidence, product specifications, and translational limitations clearly separated.

• 3-Hydroxybutyrate (BHBA): Mechanisms & Workflows

  2026-08-11

  3-hydroxybutyrate (BHBA) is an endogenous ketone body and fatty acid β-oxidation metabolite that connects energy metabolism with chromatin regulation. Evidence supports BHBA as a class I HDAC inhibitor, while recent stroke research links ketone body signaling with reduced ferroptosis, providing a rationale for carefully controlled metabolic and epigenetic experiments.

• Br-DAPI for Mechanistic Cardiac Cell Assays

  2026-08-10

  Br-DAPI is a DAPI fluorescent dye for connecting nuclear DNA measurements with cellular models of diabetic cardiomyopathy. This guide explains how to use its signal as an orthogonal assay layer alongside lipotoxicity, ER-stress, viability, and apoptosis measurements.

• Angiotensin (1-7): From RAS Biology to Translation

  2026-08-09

  Angiotensin (1-7) is more than a counter-regulatory renin–angiotensin system peptide. Its Mas receptor biology, PI3K/AKT signaling modulation, ERK pathway regulation, and emerging connection to SARS-CoV-2 spike–AXL binding create a useful framework for translational research. This article connects mechanistic rationale with practical assay design, product selection, model-specific validation, and the limitations that should guide movement from discovery studies toward therapeutic hypotheses.

• Rifampin: Mechanism, Benchmarks, and Workflow

  2026-08-08

  Rifampin is a bactericidal rifamycin antibiotic that selectively inhibits bacterial DNA-dependent RNA polymerase. Its defined target, rpoB-linked resistance, and DMSO handling profile make it useful for bacterial resistance mechanism research, transcriptional regulation studies, and controlled transcription inhibition.

• Optimized GBA1 mRNA for Gaucher Disease Therapy

  2026-08-07

  The reference study develops a human GBA1 mRNA platform in which untranslated regions, codon usage, and poly(A) tails are optimized to improve glucocerebrosidase expression and persistence. Cell and mouse experiments show lysosomal localization, functional rescue in GBA1-deficient cells, and detectable enzyme activity after lipid nanoparticle delivery, supporting further evaluation of mRNA therapy for Gaucher disease.

• Protein A/G Magnetic Beads: Practical Use and QC Protocols

  2026-08-07

  Protein A/G Magnetic Beads (SKU K1305) are engineered for efficient antibody purification and immunoprecipitation from complex samples, minimizing non-specific binding. Ideal for workflows requiring reliable Fc-region IgG capture in immunoprecipitation, co-IP, and Ch-IP, these beads are not intended for diagnostic or therapeutic applications.

724 records 10/49 page Previous Next First page 上5页 678910 下5页 Last page